Systematic meta-review of prediction studies demonstrates stable trends in bias and low PROBAST inter-rater agreement

Autor: Liselotte F.S. Langenhuijsen, Roemer J. Janse, Esmee Venema, David M. Kent, Merel van Diepen, Friedo W. Dekker, Ewout W. Steyerberg, Ype de Jong

Publikováno v: Journal of Clinical Epidemiology.

Objectives: To (1) explore trends of risk of bias (ROB) in prediction research over time following key methodological publications, using the Prediction model Risk Of Bias ASsessment Tool (PROBAST) and (2) assess the inter-rater agreement of the PROB

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22810b336ea9c17f69d4b9273ca3180a
https://doi.org/10.1016/j.jclinepi.2023.04.012

Systematic Meta-Review of Prediction Studies Demonstrates Decreasing Trends in Bias and Low Inter-Rater Agreement of the PROBAST

Autor: Liselotte Floor Sophie Langenhuijsen, Roemer J. Janse, Esmee Venema, David Kent, Merel van Diepen, Friedo W. Dekker, Ewout W. Steyerberg, Ype de Jong

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::105edd8385e63161787872f06d352cd1
https://doi.org/10.2139/ssrn.4333138

Acute kidney injury and kidney replacement therapy in COVID-19: a systematic review and meta-analysis

Autor: Ype de Jong, Esmee M. van der Willik, Joris I. Rotmans, Edouard L Fu, Merel van Diepen, Jet Milders, Olaf M. Dekkers, Vera H.W. van der Endt, Roemer J Janse, Esther De Rooij

Publikováno v: Fu, E L, Janse, R J, de Jong, Y, van der Endt, V H W, Milders, J, van der Willik, E M, de Rooij, E N M, Dekkers, O M, Rotmans, J I & van Diepen, M 2020, ' Acute kidney injury and kidney replacement therapy in COVID-19 : A systematic review and meta-analysis ', Clinical Kidney Journal, vol. 13, no. 4, pp. 550-563 . https://doi.org/10.1093/CKJ/SFAA160
Clinical Kidney Journal, 13(4), 550-563. OXFORD UNIV PRESS
Clinical Kidney Journal

BackgroundAcute kidney injury (AKI) can affect hospitalized patients with coronavirus disease 2019 (COVID-19), with estimates ranging between 0.5% and 40%. We performed a systematic review and meta-analysis of studies reporting incidence, mortality a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8164bc53938ab5bc1115cf62d7e1d217
https://doi.org/10.1093/ckj/sfaa160

Stopping versus continuing renin-angiotensin-system inhibitors after acute kidney injury and adverse clinical outcomes: an observational study from routine care data

Autor: Roemer J, Janse, Edouard L, Fu, Catherine M, Clase, Laurie, Tomlinson, Bengt, Lindholm, Merel, van Diepen, Friedo W, Dekker, Juan-Jesus, Carrero

Publikováno v: Clinical kidney journal. 15(6)

The risk-benefit ratio of continuing with renin-angiotensin system inhibitors (RASi) after an episode of acute kidney injury (AKI) is unclear. While stopping RASi may prevent recurrent AKI or hyperkalaemia, it may deprive patients of the cardiovascul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::91a97503dfd93f0141fadcdb5fc5c5a8
https://pubmed.ncbi.nlm.nih.gov/35664269